CONCERT PHARMACEUTICALS, INC.
DelistedCIK 1367920fmd_0MJ91FEDPN94X8J3TCEX3ENGXWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2022, 40 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 13 | 25 | 9 | 67 | 0 | 144 | 11 | 1 | 8 | 33 |
| Realized investment gains (losses) | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Research and development | 24 | 22 | 27 | 29 | 37 | 30 | 43 | 60 | 62 | 88 |
| Total operating expenses | 31 | 30 | 39 | 42 | 51 | 51 | 66 | 80 | 81 | 110 |
| Operating income | (19) | (4) | (31) | 25 | (51) | 93 | (56) | (79) | (73) | (78) |
| Interest expense | – | – | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | (2) | (1) | (0) | 0 | – | – | – | – | – |
| Income before taxes | – | (6) | (32) | 25 | (51) | 95 | – | – | – | – |
| Income tax expense | – | 0 | 0 | 0 | 0 | (0) | 0 | 0 | (0) | 0 |
| Net income from continuing operations | – | (6) | (32) | 24 | (51) | 96 | – | – | – | – |
| Net income | (20) | (6) | (32) | 24 | (51) | 96 | (56) | (78) | (75) | (80) |
| Net income to common shareholders | (21) | (6) | (32) | 24 | (51) | 95 | (56) | – | (75) | (80) |